The Japan-based Eisai Co., Ltd. has received approval to market and manufacture Remitoro for the treatment of relapsed or refractory PTCL or CTCL. The drug Remitoro is considered a high-need drug.
Seagen Inc. has announced new data for ADCETRIS will be presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH). An updated and interim efficacy and safety clinical trial study for ADCETRIS in classical Hodgkin lymphoma (cHL) and other CD30-expressing lymphomas as well as other rare cancers was presented in the abstracts, including five oral presentations.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4996
Published Date: Jun 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing number of patients suffering from sezary syndrome, a rise in healthcare expenditure, and a growing awareness about the disease.
The market size of sezary syndrome is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment type, diagnosis, drug class, therapy type, end users, and by region.
The T-cell receptor (TCR) gene rearrangement test segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Lack of awareness of the condition in emerging economies and limited research and approved treatments available for the disease.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.